Peer-reviewed veterinary case report
How sildenafil affects lung blood pressure in dogs
By Akabane, Ryota et al.·Published in Research in veterinary science·2020·School of Veterinary Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The effect of sildenafil on pulmonary haemodynamics in a canine model of chronic embolic pulmonary hypertension.
- Species:
- dog
Plain-English summary
A group of dogs with chronic pulmonary hypertension (PH) received different doses of sildenafil, a medication commonly used for heart and lung issues, to see how it affected their condition. After a week of treatment, the dogs showed a significant reduction in pulmonary artery pressure, which is a key indicator of heart and lung health. The higher doses of sildenafil (2 and 4 mg/kg) worked better than the lower dose, helping to improve their overall pulmonary function without causing side effects. This suggests that sildenafil can be an effective treatment for dogs suffering from pulmonary hypertension.
People also search for: dog pulmonary hypertension treatment · sildenafil for dogs · dog heart medication · symptoms of dog lung problems
Abstract
The effects of different doses of orally administered sildenafil on pulmonary haemodynamics in dogs with pulmonary hypertension (PH) have not been documented in an invasive and quantitative manner. In this study, we examined the effects of oral sildenafil using a canine model of chronic embolic PH (CEPH). This CEPH model was created by repeatedly injecting microspheres through a catheter into the pulmonary artery under general anaesthesia at regular weekly intervals over several months. The CEPH dogs received 1, 2 or 4 mg/kg of sildenafil orally twice a day for seven days. Then, haemodynamic measurements including pulmonary artery pressure (PAP), systemic artery pressure (SAP), pulmonary artery wedge pressure (PAWP), right atrial pressure (RAP) and cardiac output (CO) were obtained after seven days of sildenafil administration via right heart catheterisation and oscillometric blood pressure measurements. Sildenafil was well tolerated in this study. Sildenafil administered at doses of 2 and 4 mg/kg significantly decreased systolic PAP compared with before administration. In addition, all doses of sildenafil significantly decreased the mean and diastolic PAP. Furthermore, 4 mg/kg of sildenafil significantly decreased PAP compared with 1 mg/kg. Sildenafil also significantly decreased pulmonary vascular resistance without notable changes in SAP or systemic vascular resistance. The PAWP, RAP and CO did not increase significantly at any doses. In conclusion, the oral administration of sildenafil to CEPH models decreased PAP in a dose-dependent manner.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32961474/